Lisata Therapeutics Framtida tillväxt
Future kriterier kontrolleras 0/6
Lisata Therapeutics s intäkter förväntas minska med 5.4% per år medan dess årliga intäkter förväntas växa med 127.8% per år. EPS förväntas tillväxt med 20.8% per år.
Viktig information
-5.4%
Tillväxttakt i vinsten
20.81%
Tillväxttakt för EPS
| Biotechs vinsttillväxt | 25.5% |
| Intäkternas tillväxttakt | 127.8% |
| Framtida avkastning på eget kapital | n/a |
| Bevakning av analytiker | Low |
| Senast uppdaterad | 17 May 2026 |
Senaste uppdateringarna om framtida tillväxt
Recent updates
Uppdatering av berättelse • May 02
LSTA: Higher Growth Outlook Will Offset Going Concern Liquidity Risk
Analysts have reset their 12 month price target for Lisata Therapeutics from $11.33 to $9.50, reflecting updated assumptions for revenue growth, profit margin, and a lower forward P/E multiple in their models. What's in the News Lisata Therapeutics filed its 10 K on March 12, 2026 for the period ending December 31, 2025, providing updated audited financial statements and disclosures for the year.
Uppdatering av berättelse • Apr 17
LSTA: Kuva Cash Deal Will Support Future Upside Potential
Analysts have adjusted their price target on Lisata Therapeutics to $15.00 from $15.00, reflecting updated assumptions for discount rate, revenue growth, profit margin and future P/E while referencing the recent downgrade highlighted in Street research. Analyst Commentary Bullish analysts looking at Lisata Therapeutics are framing the updated US$15.00 price target within a wider debate about how quickly the company can execute on its pipeline and how much of that potential is already reflected in the shares.Uppdatering av berättelse • Apr 03
LSTA: Kuva Cash Deal And Pipeline Milestones Will Support Future Upside Potential
Analysts have reduced their price target on Lisata Therapeutics to $15.00, citing updated assumptions on the discount rate, revenue growth, profit margin, and future P/E following recent research that included a downgrade at Brookline. Analyst Commentary Recent research points to a more cautious stance on Lisata Therapeutics, yet there are still several areas that bullish analysts highlight as potential positives for long term holders.Uppdatering av berättelse • Mar 20
LSTA: Brookline Downgrade And Kuva Cash Deal Will Reset Upside Expectations
Analysts have revised their price target for Lisata Therapeutics to $15.00, reflecting updated assumptions around revenue growth, profit margins, and a lower future P/E, as outlined in recent Street research. Analyst Commentary Recent Street research around Lisata Therapeutics highlights a wide range of views, with some investors focusing on execution risks and others pointing to upside potential if key assumptions play out as expected.Uppdatering av berättelse • Mar 05
LSTA: Brookline Downgrade And Acquisition Offer Will Reset Expectations For Upside
Analysts have adjusted their price target on Lisata Therapeutics to $15.00. The change reflects updated assumptions around revenue growth, profit margins and future P/E expectations following recent research, including a downgrade at Brookline.Uppdatering av berättelse • Feb 18
LSTA: Pending Kuva Acquisition And Contingent Rights Will Support Future Upside
Analysts have reduced their price target on Lisata Therapeutics from $13.00 to approximately $11.33. They cited updated assumptions around fair value, discount rate, long-term revenue growth, profit margins, and future P/E multiples following recent changes in research coverage.Uppdatering av berättelse • Feb 04
LSTA: Acquisition Offer And Downgrade Reset Expectations Before Potential Upside
Analysts have trimmed their price target on Lisata Therapeutics from US$15 to US$15.00, reflecting updated assumptions around revenue growth, profit margins, discount rates, and a higher future P/E multiple following recent research, including a downgrade from Brookline. Analyst Commentary Despite the recent trim in the headline price target, bullish analysts still see room for upside if Lisata executes on its plans and delivers against current expectations.Uppdatering av berättelse • Jan 21
LSTA: Refined Risk Assumptions Will Support Future Upside Despite Recent Downgrade
Analysts have slightly reduced their fair value estimate to US$13.00, citing modest adjustments to the discount rate, long term profit margin expectations, and a lower implied future P/E as they reassess Lisata Therapeutics following a recent downgrade in Street research. Analyst Commentary Bullish Takeaways Bullish analysts view the revised US$13.00 fair value as still reflecting upside potential, provided that execution on key clinical and operational milestones tracks internal expectations.Uppdatering av berättelse • Jan 07
LSTA: Improved Profitability Assumptions Will Support Strong Future Upside Potential
Analysts have modestly lifted their price target for Lisata Therapeutics, citing slightly improved profit margin assumptions at 16.24% and a lower future P/E estimate of 103.37x as key drivers of their updated valuation. Valuation Changes Fair Value: Remains unchanged at 13.0, suggesting the overall valuation anchor has been kept steady.Uppdatering av berättelse • Dec 24
LSTA: Upcoming Pancreatic Cancer Data And Catalent Deal Will Drive Shares
Analysts have reduced their price target on Lisata Therapeutics from 32.00 dollars to 15.00 dollars, citing higher discount rates despite stronger projected revenue growth, improved profit margins, and a materially lower future price-to-earnings multiple. What's in the News Lisata Therapeutics and Catalent signed a global product license agreement granting Catalent non exclusive worldwide rights to incorporate certepetide into antibody drug conjugates using its SMARTag technology platform, including the ability to partner with third parties (Key Developments) Under the Catalent collaboration, Lisata is eligible for more than 10 million dollars in tiered study initiation milestone payments plus revenue sharing on future product sales and partnerships (Key Developments) Certepetide, Lisata's proprietary iRGD cyclic peptide, has shown favorable safety, tolerability, and clinical activity in trials aimed at improving the effectiveness of standard of care chemotherapy for pancreatic cancer and other solid tumors (Key Developments) Certepetide has received multiple regulatory designations, including Fast Track and Orphan Drug Designation for pancreatic cancer in the U.S. and E.U., Orphan Drug Designation for glioma and osteosarcoma in the U.S., and Rare Pediatric Disease Designation for osteosarcoma in the U.S. (Key Developments) Preliminary data from the PDAC cohort of the Phase 1/2a CENDIFOX trial of certepetide plus FOLFIRINOX based therapies will be presented at the AACR Special Conference in Cancer Research on Advances in Pancreatic Cancer Research on September 29, 2025, in Boston, Massachusetts (Key Developments) Valuation Changes Fair Value Estimate: Reduced significantly from 32 dollars to 15 dollars per share, reflecting a more conservative assessment despite stronger fundamentals.Uppdatering av berättelse • Dec 09
LSTA: Upcoming Cancer Trial Milestones Will Drive Strong Upside Potential
Analysts have nudged their price target on Lisata Therapeutics slightly higher to 13.00 dollars from 13.00 dollars, reflecting modest adjustments to the discount rate and long-term valuation assumptions, despite largely unchanged growth and margin expectations. What's in the News Lisata Therapeutics and Catalent entered a global product license agreement granting Catalent worldwide, non exclusive rights to use certepetide in antibody drug conjugates developed on its SMARTag platform, with Lisata eligible for over 10 million dollars in tiered milestone payments plus revenue sharing on future sales and partnerships (Key Developments) Certepetide, Lisata's proprietary internalizing RGD cyclic peptide, will be evaluated by Catalent as a payload across multiple ADCs targeting difficult to treat diseases.Uppdatering av berättelse • Nov 25
LSTA: Global Licensing Milestones And Trial Results Will Drive Future Upside
Analysts have raised their price target for Lisata Therapeutics slightly, increasing it from $13.00 to $13.00 per share. This reflects updated projections for profitability and valuation metrics.Uppdatering av berättelse • Nov 09
LSTA: Milestone Payments And Clinical Progress Will Drive Future Upside
Analysts have revised their price target for Lisata Therapeutics from $20.67 to $13.00, citing updated financial assumptions and outlook. What's in the News Lisata Therapeutics and Catalent have entered a global product license agreement, granting Catalent non-exclusive rights to develop and commercialize bioconjugate products containing certepetide using the SMARTag technology platform.Analysartikel • Aug 13
Is Lisata Therapeutics (NASDAQ:LSTA) In A Good Position To Deliver On Growth Plans?
We can readily understand why investors are attracted to unprofitable companies. For example, although...Analysartikel • Apr 26
We Think Lisata Therapeutics (NASDAQ:LSTA) Needs To Drive Business Growth Carefully
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Ny berättelse • Apr 14
Certepetide Advancements And Regulatory Approvals Will Set New Care Standards
Advancements in certepetide and regulatory achievements could expedite market entry, fostering revenue growth and enhancing treatment standards.Analysartikel • Dec 24
Here's Why We're Watching Lisata Therapeutics' (NASDAQ:LSTA) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Analysartikel • Jul 15
Here's Why We're Watching Lisata Therapeutics' (NASDAQ:LSTA) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Analysartikel • Mar 22
Is Lisata Therapeutics (NASDAQ:LSTA) In A Good Position To Deliver On Growth Plans?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Analysartikel • Sep 15
We Think Caladrius Biosciences (NASDAQ:CLBS) Needs To Drive Business Growth Carefully
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Seeking Alpha • Sep 14
Caladrius rallies on approval of merger, name change to Lisata Therapeutics
Caladrius Biosciences (NASDAQ:CLBS) announced that its stockholders approved all of the merger-related proposals by Caladrius and Cend Therapeutics, and the transactions contemplated thereby, including the Merger and the issuance of shares of Caladrius’ common stock to Cend’s stockholders. Subsequent to the stockholders’ approval, the Caladrius Board of Directors approved a reverse stock split of Caladrius’ common stock at a ratio of one new share for every fifteen shares outstanding. The reverse stock split will become effective today, Sept. 14, 2022, at 5:00pm EST. The consolidated common shares for the combined company, which will be renamed Lisata Therapeutics, are expected to commence trading on Nasdaq under the symbol “LSTA” on Sept. 15, 2022, at 9:30am EST. CLBS +39.28% premarket to $0.71.Seeking Alpha • Aug 04
Caladrius Biosciences GAAP EPS of -$0.11 beats by $0.01
Caladrius Biosciences press release (NASDAQ:CLBS): Q2 GAAP EPS of -$0.11 beats by $0.01. As of June 30, 2022, the company had cash, cash equivalents and marketable securities of approximately $73 million. Merger with Cend Therapeutics remains on track to close in Q3.Analysartikel • May 02
We Think Caladrius Biosciences (NASDAQ:CLBS) Needs To Drive Business Growth Carefully
We can readily understand why investors are attracted to unprofitable companies. For example, although...Analysartikel • Jan 05
We're Keeping An Eye On Caladrius Biosciences' (NASDAQ:CLBS) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Analysartikel • May 09
Companies Like Caladrius Biosciences (NASDAQ:CLBS) Are In A Position To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Analysartikel • Nov 30
Here's Why We're Not Too Worried About Caladrius Biosciences' (NASDAQ:CLBS) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Prognoser för vinst- och omsättningstillväxt
| Datum | Intäkter | Intäkter | Fritt kassaflöde | Kassaflöde från rörelsen | Genomsnittligt Antal analytiker |
|---|---|---|---|---|---|
| 12/31/2028 | 7 | -19 | N/A | N/A | 1 |
| 12/31/2027 | N/A | -21 | N/A | N/A | 1 |
| 12/31/2026 | N/A | -18 | N/A | N/A | 1 |
| 3/31/2026 | 0 | -16 | -14 | -14 | N/A |
| 12/31/2025 | 0 | -17 | -16 | -16 | N/A |
| 9/30/2025 | 1 | -18 | -17 | -17 | N/A |
| 6/30/2025 | 1 | -19 | -16 | -16 | N/A |
| 3/31/2025 | 1 | -19 | -18 | -18 | N/A |
| 12/31/2024 | 1 | -20 | -19 | -19 | N/A |
| 9/30/2024 | N/A | -21 | -19 | -19 | N/A |
| 6/30/2024 | N/A | -21 | -20 | -20 | N/A |
| 3/31/2024 | N/A | -20 | -19 | -19 | N/A |
| 12/31/2023 | N/A | -21 | -20 | -20 | N/A |
| 9/30/2023 | N/A | -21 | -22 | -22 | N/A |
| 6/30/2023 | N/A | -54 | -23 | -23 | N/A |
| 3/31/2023 | N/A | -56 | -24 | -24 | N/A |
| 12/31/2022 | N/A | -54 | -21 | -21 | N/A |
| 9/30/2022 | N/A | -55 | -20 | -19 | N/A |
| 6/30/2022 | N/A | -25 | -21 | -20 | N/A |
| 3/31/2022 | N/A | -24 | -20 | -20 | N/A |
| 12/31/2021 | N/A | -27 | -22 | -22 | N/A |
| 9/30/2021 | N/A | -26 | -23 | -23 | N/A |
| 6/30/2021 | N/A | -25 | -22 | -22 | N/A |
| 3/31/2021 | N/A | -12 | -13 | -13 | N/A |
| 12/31/2020 | N/A | -8 | -9 | -9 | N/A |
| 9/30/2020 | N/A | -8 | -7 | -7 | N/A |
| 6/30/2020 | N/A | -7 | -8 | -8 | N/A |
| 3/31/2020 | N/A | -19 | -18 | -18 | N/A |
| 12/31/2019 | N/A | -19 | N/A | -19 | N/A |
| 9/30/2019 | N/A | -18 | N/A | -18 | N/A |
| 6/30/2019 | N/A | -17 | N/A | -18 | N/A |
| 3/31/2019 | N/A | -16 | N/A | -19 | N/A |
| 12/31/2018 | N/A | -16 | N/A | -20 | N/A |
| 9/30/2018 | N/A | -17 | N/A | -21 | N/A |
| 6/30/2018 | N/A | -17 | N/A | -22 | N/A |
| 3/31/2018 | N/A | -14 | N/A | -17 | N/A |
| 12/31/2017 | N/A | -16 | N/A | -21 | N/A |
| 9/30/2017 | N/A | -18 | N/A | -20 | N/A |
| 6/30/2017 | N/A | -20 | N/A | -20 | N/A |
| 3/31/2017 | -7 | -26 | N/A | -26 | N/A |
| 12/31/2016 | N/A | -31 | N/A | -24 | N/A |
| 9/30/2016 | 8 | -59 | N/A | -29 | N/A |
| 6/30/2016 | 13 | -64 | N/A | -32 | N/A |
| 3/31/2016 | 27 | -74 | N/A | -33 | N/A |
| 12/31/2015 | 22 | -81 | N/A | -39 | N/A |
| 9/30/2015 | 20 | -59 | N/A | -41 | N/A |
| 6/30/2015 | 18 | -65 | N/A | -46 | N/A |
Analytiker Framtid Tillväxt Prognoser
Intäkter kontra sparande: LSTA förväntas förbli olönsam under de kommande 3 åren.
Resultat vs marknad: LSTA förväntas förbli olönsam under de kommande 3 åren.
Höga tillväxtresultat: LSTA förväntas förbli olönsam under de kommande 3 åren.
Intäkt vs marknad: LSTA förväntas inte ha några intäkter nästa år.
Hög tillväxtintäkter: LSTA förväntas inte ha några intäkter nästa år.
Tillväxtprognoser för vinst per aktie
Framtida avkastning på eget kapital
Framtida ROE: Otillräcklig data för att avgöra om LSTA s avkastning på eget kapital förväntas bli hög om tre år
Upptäck tillväxtföretag
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/21 21:28 |
| Aktiekurs vid dagens slut | 2026/05/21 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Lisata Therapeutics, Inc. bevakas av 11 analytiker. 1 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Jan Wald | Benchmark Company |
| Brian Kemp Dolliver | Brookline Capital Markets |
| Kumaraguru Raja | Brookline Capital Markets |